China Approves Veridex's CellSearch Test for Metastatic Breast Cancer | GenomeWeb

NEW YORK (GenomeWeb News) – Chinese regulators approved Veridex's CellSearch circulating tumor test for aiding in the diagnosis of women with metastatic breast cancer, Veridex announced on Wednesday.

The Johnson & Johnson firm said the test is the first and only approved CTC test for cancer patients in China, and the approval from the China State Food and Drug Administration makes China the seventh country outside of the US and the European Union to clear CellSearch as an aid in the monitoring of patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of 200 bird species, and more.

The Australian High Court rules that isolated genetic material cannot be patented.

The startup incubator Y Combinator is launching a nonprofit research lab.

In Genome Research this week: vervet genome, tandem repeats affect gene expression in great apes, and more.

Sponsored by

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit. 

Sponsored by

This webinar will focus on a range of research and clinical applications enabled by improvements in mate pair technology for whole genome sequencing. 

Sponsored by
Oracle Health Sciences

Brian Wells of Penn Medicine will detail how his team's "PennOmics" integrated healthcare data warehouse accelerates clinical trial recruitment at the point of care, accepts data from wearables, and does it all in a secure, HIPAA- and research-compliant fashion.